Finasteride 1 mg vs 5 mg Side Effects Compared
How do side effects differ between the 1 mg hair loss dose and the 5 mg prostate dose?
Line the two labels up side by side and the 5 mg tablet looks several times more dangerous than the 1 mg one. Most of that gap isn't the extra four milligrams you're swallowing, it's that the two doses were tested in men decades apart in age and followed for four years against one. Read the tables the honest way and you're looking at effects of similar character at both strengths.
| Reported Effect | 1 mg, 12 months | 5 mg, first year |
|---|---|---|
| Decreased libido | 1.8% vs 1.3% placebo | 6.4% vs 3.4% placebo |
| Erectile difficulty | 1.3% vs 0.7% placebo | 8.1% vs 3.7% placebo |
| Reduced ejaculate volume | 1.2% vs 0.7% placebo | 3.7% vs 0.8% placebo |
| Ages studied | 18 to 41 | 45 to 78 |
Serum DHT falls by roughly 71 percent at 1 mg and 72 percent at 5 mg, so the two doses produce nearly the same hormonal effect and the gap in reported side effect rates is driven mainly by trial age and follow-up length.
Why does a five-fold increase in dose not produce a five-fold increase in DHT suppression?
Saturation explains all of it. Once you've got enough drug on board to occupy most of the type II enzyme, the next four milligrams have nothing left to bind to. That's why the hair loss dose was set where it was rather than higher.
- 1 mg daily: Serum DHT down about 71 percent, scalp DHT down about 60 percent.
- 5 mg daily: Serum DHT down about 72 percent, roughly one point more.
- Type I enzyme: Barely touched at either strength, which caps total suppression.
- Onset: DHT suppression is measurable within 24 hours of the first tablet.
Because 1 mg and 5 mg suppress serum DHT within about one percentage point of each other, any hormonally driven side effect should be broadly similar at both strengths.
How do sexual side effect rates compare between the two doses in clinical trial data?
Take the label tables literally and the higher dose looks four to six times worse, which is exactly why you shouldn't take them literally. The column most readers skip is the placebo one, which runs two to five times higher in the older group before anyone swallows a tablet. What you want is the gap between drug and placebo inside each study, not the raw percentage.
| Measure | 1 mg, 12 months | 5 mg, first year |
|---|---|---|
| Decreased libido | 1.8% vs 1.3% | 6.4% vs 3.4% |
| Erectile complaint | 1.3% vs 0.7% | 8.1% vs 3.7% |
| Excess over placebo | Under 1 point | About 3 to 4 points |
| Stopped over a side effect | 1.4% vs 1.6% on placebo | Most men stayed on treatment |
The drug-attributable excess over placebo is under one percentage point at 1 mg and about three to four percentage points at 5 mg, far narrower than the raw label figures suggest.
Which side effects are reported mainly at the higher dose rather than the lower one?
Only a short list genuinely belongs to the higher dose, and breast tissue heads it. Block the conversion of testosterone to DHT and you leave slightly more testosterone available to convert to estradiol, and chest tissue notices small shifts like that in a way your scalp never does.
- Breast enlargement: About 0.5 percent in year one at 5 mg, 1.8 percent by year four.
- Breast tenderness: About 0.4 percent in year one, roughly 0.7 percent after that.
- Ejaculate volume: A difference of degree, more noticeable after years on the higher dose.
- High-grade tumour finding: Sits only on the 5 mg label, still argued over as a detection artefact.
Breast enlargement and breast tenderness are the clearest dose-related effects, named in the 5 mg label at about 0.5 and 0.4 percent in the first year while appearing at 1 mg only as uncommon post-marketing reports.
How does each dose affect PSA testing and prostate cancer screening?
Both strengths interfere with the PSA test, and the belief that only the prostate dose does is the practical hazard here. If you're on either tablet, get it written into your notes now, because every result has to be read by someone who knows it's in your system.
The 5 mg dose halves serum PSA within six months so any on-treatment result must be doubled, and the 1 mg dose still lowers mean PSA from 0.7 to 0.5 nanograms per millilitre over twelve months.
How do the age and health of the trial populations distort a direct comparison of the two doses?
You're not comparing two doses when you compare the two labels, you're comparing two different experiments. One followed men aged eighteen to forty-one for twelve months; the other followed men aged forty-five to seventy-eight, half of them sixty-five or older, for four years. Three separate things stack up before the milligrams get a look in.
No large randomised trial has given 1 mg and 5 mg to the same kind of man, so the only defensible comparison is drug against placebo within each study, which lands under one percentage point at the lower dose and around three to four at the higher.
Do side effects at either dose resolve after stopping the medication?
For most men the answer is yes, and often without stopping at all. In the four-year prostate study, sexual complaints cleared while treatment continued in about 12 percent of men on finasteride against 19 percent on placebo, and only about 4 percent left the study over one.
- While you keep taking it: Roughly 12 percent of complaints resolve on treatment, which is why so few men actually stop.
- The first day off: Plasma half-life is about six hours in younger men and eight in older ones.
- Two weeks off: Serum DHT is back to baseline, so anything driven straight by DHT suppression should be gone inside a month.
- Twelve months off: Hair held by the 1 mg dose is generally lost, and prostate volume returns close to baseline within a few months at 5 mg.
Serum DHT returns to baseline within about two weeks of stopping at either strength, which is why a defined two-week break with the symptom tracked in writing beforehand is the informative way to test whether the tablet is responsible.
What is known about persistent symptoms after discontinuation at each dose?
This is the part where the honest answer is that nobody knows the rate, and you should be wary of anyone who tells you otherwise in either direction. Both labels now carry post-marketing wording about sexual dysfunction continuing after treatment stops, and that wording exists because reports exist, not because a rate has been measured.
- Both labels: Post-marketing reports of erectile, libido and ejaculation disorders continuing after stopping.
- Reporting skew: Reports cluster at 1 mg, where users are young, healthy and quick to attribute symptoms.
- Evidence quality: Spontaneous reports with no denominator, no control arm, no comparison group.
- Controlled trials: Found no excess of persistent symptoms at either dose, though a rare effect would stay invisible.
The risk of a persistent problem after stopping appears low and unquantified rather than zero, and it is not clearly different between the 1 mg and 5 mg doses.
Which precautions and contraindications apply regardless of which dose is taken?
This is the simplest part of the comparison, because none of it shifts with strength. The absolute rule is about pregnancy, and it applies to the cosmetic tablet exactly as it applies to the therapeutic one.
At both 1 mg and 5 mg the medication is contraindicated in women who are or may become pregnant, and they must not handle broken or crushed tablets because the film coating is the only barrier to the active ingredient.
